The outcome of patients with EGFR-mutated NSCLC has significantly improved with the introduction of EGFR-tyrosine kinase inhibitors (TKIs), with a median overall survival (OS) of more than 3 years [2]. Here, EGFR is linked to non-small cell lung carcinoma.